334 related articles for article (PubMed ID: 20421698)
21. Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome.
Coppus AM; Schuur M; Vergeer J; Janssens AC; Oostra BA; Verbeek MM; van Duijn CM
Neurobiol Aging; 2012 Sep; 33(9):1988-94. PubMed ID: 21958962
[TBL] [Abstract][Full Text] [Related]
22. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease.
Baranowska-Bik A; Bik W; Wolinska-Witort E; Martynska L; Chmielowska M; Barcikowska M; Baranowska B
Neuro Endocrinol Lett; 2008 Feb; 29(1):75-9. PubMed ID: 18283248
[TBL] [Abstract][Full Text] [Related]
23. Plasma β-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease.
González-Martínez Á; Rosado B; Pesini P; Suárez ML; Santamarina G; García-Belenguer S; Villegas A; Monleón I; Sarasa M
Exp Gerontol; 2011 Jul; 46(7):590-6. PubMed ID: 21377518
[TBL] [Abstract][Full Text] [Related]
24. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.
Mruthinti S; Buccafusco JJ; Hill WD; Waller JL; Jackson TW; Zamrini EY; Schade RF
Neurobiol Aging; 2004 Sep; 25(8):1023-32. PubMed ID: 15212827
[TBL] [Abstract][Full Text] [Related]
25. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
26. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
27. Multiplex immunoassay measurement of amyloid-β
Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease.
Ait-ghezala G; Abdullah L; Volmar CH; Paris D; Luis CA; Quadros A; Mouzon B; Mullan MA; Keegan AP; Parrish J; Crawford FC; Mathura VS; Mullan MJ
Cytokine; 2008 Nov; 44(2):283-7. PubMed ID: 18835787
[TBL] [Abstract][Full Text] [Related]
29. Electrophoretic separation of amyloid beta peptides in plasma.
Lewczuk P; Esselmann H; Bibl M; Paul S; Svitek J; Miertschischk J; Meyrer R; Smirnov A; Maler JM; Klein C; Otto M; Bleich S; Sperling W; Kornhuber J; Rüther E; Wiltfang J
Electrophoresis; 2004 Oct; 25(20):3336-43. PubMed ID: 15490456
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
31. Ultrafiltrate of blood plasma modulates amyloid-β aggregation.
Nowicka A; Szczepankiewicz AA; Jaklewicz A; Filipek A; Barcikowska M; Elbaum D
J Alzheimers Dis; 2011; 23(1):1-5. PubMed ID: 20930295
[TBL] [Abstract][Full Text] [Related]
32. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease.
Kuo YM; Emmerling MR; Lampert HC; Hempelman SR; Kokjohn TA; Woods AS; Cotter RJ; Roher AE
Biochem Biophys Res Commun; 1999 Apr; 257(3):787-91. PubMed ID: 10208861
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer's disease.
Krishnan S; Rani P
Biol Trace Elem Res; 2014 May; 158(2):158-65. PubMed ID: 24682919
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
[TBL] [Abstract][Full Text] [Related]
35. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
36. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
[TBL] [Abstract][Full Text] [Related]
37. Plasma biomarkers of Alzheimer's disease.
Kawarabayashi T; Shoji M
Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
[TBL] [Abstract][Full Text] [Related]
38. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study.
Lambert JC; Schraen-Maschke S; Richard F; Fievet N; Rouaud O; Berr C; Dartigues JF; Tzourio C; Alpérovitch A; Buée L; Amouyel P
Neurology; 2009 Sep; 73(11):847-53. PubMed ID: 19752451
[TBL] [Abstract][Full Text] [Related]
39. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
[TBL] [Abstract][Full Text] [Related]
40. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
